Search Press releases Keywords From To 17 Jun 2026 UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI[®]▼ (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d) Read More 17 Jun 2026 UCB completes acquisition of Candid Therapeutics, strengthening next generation immunology pipeline Read More 5 Jun 2026 New EULAR 2026 data show CIMZIA[®] (certolizumab pegol) delivered consistent effect in rheumatoid arthritis, regardless of rheumatoid factor (RF) levels Read More 4 Jun 2026 EULAR 2026: Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus Read More 3 Jun 2026 BIMZELX[®](bimekizumab) data at EULAR 2026 show early and sustained inflammation control can improve patient reported outcomes and limit disease progression in PsA and axSpA Read More 2 Jun 2026 UCB completes acquisition of Neurona Therapeutics, advancing its leadership as innovator in epilepsy through regenerative science Read More Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Page 1 of 65 Next page Next Last page Stay up-to-date on the latest news and information from UCB Subscribe
